Quantum Cyber Launches $100M ATM Program with Titan Partners
QUCY has more than doubled off its 52-week low of $0.3.
Summary
Quantum Cyber filed a prospectus supplement for a new $100 million at-the-market offering program with Titan Partners as sales agent, following its earlier ATM termination and $250 million shelf registration.
Key Events · Financing and Capital Events · QUCY
-
New $100M ATM Program
Sales Agreement dated October 9, 2026 with Titan Partners Securities LLC to sell up to $100,000,000 of ordinary shares from time to time at market prices.
-
Massive Potential Dilution
At the assumed offering price of $1.43 per share, the program would issue up to 69,930,070 new shares — an 80% increase over the 87,219,235 shares currently outstanding.
-
Immediate Dilution to New Investors
New investors would experience immediate dilution of $0.73 per share, with pro forma as adjusted net tangible book value of $0.70 per share after the full offering.
-
Going Concern Risk
The company's auditor has included a going concern explanatory paragraph, and the Q2 10-Q showed a $16.1M loss with no revenue — this ATM is critical for funding operations.
Analysis · QUCY · Life Sciences
A new at-the-market sales agreement with Titan Partners allows Quantum Cyber to sell up to $100 million of ordinary shares. For a company with a market cap of roughly $113 million and an auditor's going concern warning, this is a substantial capital raise. The ATM structure lets the company drip-feed shares into the market at prevailing prices, creating a significant overhang on the stock. At the assumed offering price of $1.43 per share, the full program would issue approximately 69.9 million new shares — nearly doubling the current outstanding share count of 87.2 million. New investors would face immediate dilution of $0.73 per share. The capital is needed to fund the company's pivot to AI and quantum computing for autonomous systems, but the dilution risk is severe for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 28.2% of the 1631 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QUCY was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.5M. The 52-week trading range was $0.30 to $4.93. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.